Glofitamab

Unassigned

New Medicines

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Bi-specific anti-CD20/CD3 antibody engaging T and B cells simultaneously
Diffuse large B-cell lymphoma (DLBCL) account for 30-58% of all NHLs. The overall annual incidence of DLBCL in Europe is 3.8 per 100,000 but the incidence increases with age and varies considerably across Europe [1].
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Intravenous